Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

In the first quarter, Biontech recorded a net loss of EUR 416 million due to increased research costs. However, research gives hope.

In the first quarter, the pharmaceutical company Biontech has made a large amount of money for research work. The company wants to speed up the approval of cancer drugs.

The loss of millions of 2024 is resounding. In the coming year, the Mainzers want to obtain a market approval for cancer therapy.

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

A proposal by HHS Secretary Robert F. Kennedy Jr. to change the approval standard of new vaccines shouldn't affect BioNTech's Covid-19 franchise, the company told investors Monday. Biotech and pharma companies are trying to figure ...

MAINZ. How did the business of the Corona vaccine manufacturer Biontech start in the new financial year after the loss of millions in 2024? On this Monday, the Mainzers will present their figures for the first quarter of 2025. Statements in direction 2026 are expected to be in focus. Then the company wants to obtain a first market approval for a cancer therapy based on mRNA. In 2024, the net loss [...]